Table 1_Adverse events associated with medical cannabis reported within a centralized call

Table 1 from a retrospective analysis of adverse events (AEs) reported by patients in the Minnesota Medical Cannabis Program between 2015 and 2021. The data includes 237 calls from 225 individuals reporting 692 symptoms, with details on AE severity, cannabinoid doses, product types, and patient demographics. The dataset was authored by Sílvia M. Illamola and shared under a CC-BY-4.0 license.

Use Cases

• Analyze associations between adverse event severity and daily THC/CBD doses based on the reported dose data.
• Characterize the types of symptoms and product formulations most commonly implicated in adverse events based on the reported symptom and product type data.
• Model the likelihood of treatment discontinuation following an adverse event based on the reported outcome data.
• Investigate demographic patterns in adverse event reporting based on the collected patient demographic data.

Strengths

• Includes 692 reported symptoms from 225 individuals, providing a basis for analysis.
• Covers a 7-year time range (2015-2021) for longitudinal perspective.
• Contains specific metrics such as 32.5% treatment discontinuation rate and statistical significance (p < 0.05) for dose-severity associations.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Data is limited to a single licensed manufacturer in Minnesota, which may not be generalizable.
• The dataset is very small (31.0 KB), indicating limited scope.

Provenance

Source

Retrospective analysis of calls to a centralized call center for the Minnesota Medical Cannabis Program.

Collection Method

Data collected from voluntary reports by patients enrolled in the program.

Time Range

2015 to 2021

Freshness

Last updated 2026-05-04 09:58:02; freshness should be verified.

Geography

Minnesota, United States